文献速递耳科与耳神经小儿耳鼻咽喉

德国单中心年龄分布均衡的大队列中靶向听力损失基因 panel 测序的诊断产出:一项八年研究

Diagnostic Yield of Targeted Hearing Loss Gene Panel Sequencing in a Large German Cohort With a Balanced Age Distribution from a Single Diagnostic Center: An Eight-year Study.
PubMed 文献 · Ear Hear · 2022-01-01

该研究对德国西南部单中心 305 例疑似遗传性听力损失的先证者/家系(2011-2018 年,年龄分布均衡)进行单基因筛查(n=21)或定制听力损失基因 panel 测序(n=284),并按当前 ACMG/AMP 指南回顾性重分析。结果为 75 例(25%)先证者确立遗传诊断,涉及 35 个基因的 75 个致病变异,包括 16 个新致病变异和 9 个医学显著变异重分类。诊断率和基因分布高度依赖表型特征,常染色体显性基因占 37%、隐性占 60%、X 连锁占 3%。

要点

  • 305 例疑似遗传性听力损失先证者中 75 例(25%)确立遗传诊断。
  • 最常见的五个基因依次为 GJB2(25%)、MYO15A、WFS1、SLC26A4 和 COL11A1(各 5%)。
  • 常染色体隐性遗传家族史合并早发和更高程度听力损失可使解决率显著提高至 60%。

核心结论

  • 靶向听力损失基因 panel 分析在常规临床环境中是确保适当诊断产出的有效工具,包括识别新变异和医学显著重分类。
  • 解决率对表型特征高度敏感;该队列年龄分布均衡且偏向晚发听力损失,揭示了常染色体显性基因对诊断的显著较大贡献,可能代表其他人群中其他年龄均衡队列。

研究设计与样本

  • 对 305 例疑似遗传性听力损失且年龄分布均衡的先证者/家系进行基因检测,历时 8 年(2011-2018 年),个体按年龄和性别分布代表区域人群。
  • 基因检测流程包括单基因筛查(n=21)和定制设计的听力损失基因 panel 测序(n=284),靶向已知的非综合征性和综合征性听力损失基因,用于诊断设置。
  • 通过应用当前美国医学遗传学与基因组学学会/分子病理学协会(ACMG/AMP)指南对测序数据进行回顾性重分析。

主要发现

  • 75 例(25%)先证者确立遗传诊断,涉及 35 个基因的 75 个致病变异,包括 16 个新致病变异和 9 个医学显著变异重分类。
  • 近一半已解决病例(47%;n=35)与五个最常受累基因的变异相关:GJB2(25%)、MYO15A、WFS1、SLC26A4 和 COL11A1(各 5%)。
  • 近四分之一病例(23%;n=17)与另外七个基因(TMPRSS3、COL4A3、LOXHD1、EDNRB、MYO6、TECTA 和 USH2A)的变异相关。
  • 其余三分之一单病例(33%;n=25)与 25 个不同基因的变异相关。
  • 常染色体隐性遗传家族史合并早发和更高程度听力损失显著提高解决率至 60%,而晚发和较低程度听力损失产生显著更少诊断;常染色体显性基因占已解决病例 37%、常染色体隐性基因占 60%、X 连锁基因占 3%;综合征性/非综合征性听力损失模拟基因在 27% 的遗传诊断中受累。

临床怎么用

  • 靶向听力损失基因 panel 分析在常规临床环境中是确保适当诊断产出的有效工具,包括识别新变异和医学显著重分类。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Hereditary hearing loss exhibits high degrees of genetic and clinical heterogeneity. To elucidate the population-specific and age-related genetic and clinical spectra of hereditary hearing loss, we investigated the sequencing data of causally associated hearing loss genes in a large cohort of hearing-impaired probands with a balanced age distribution from a single center in Southwest Germany. DESIGN: Genetic testing was applied to 305 hearing-impaired probands/families with a suspected genetic hearing loss etiology and a balanced age distribution over a period of 8 years (2011-2018). These individuals were representative of the regional population according to age and sex distributions. The genetic testing workflow consisted of single-gene screening (n = 21) and custom-designed hearing loss gene panel sequencing (n = 284) targeting known nonsyndromic and syndromic hearing loss genes in a diagnostic setup. Retrospective reanalysis of sequencing data was conducted by applying the current American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines. RESULTS: A genetic diagnosis was established for 75 (25%) of the probands that involved 75 causal variants in 35 genes, including 16 novel causal variants and 9 medically significant variant reclassifications. Nearly half of the solved cases (47%; n = 35) were related to variants in the five most frequently affected genes: GJB2 (25%), MYO15A, WFS1, SLC26A4, and COL11A1 (all 5%). Nearly one-quarter of the cases (23%; n = 17) were associated with variants in seven additional genes (TMPRSS3, COL4A3, LOXHD1, EDNRB, MYO6, TECTA, and USH2A). The remaining one-third of single cases (33%; n = 25) were linked to variants in 25 distinct genes. Diagnostic rates and gene distribution were highly dependent on phenotypic characteristics. A positive family history of autosomal-recessive inheritance in combination with early onset and higher grades of hearing loss significantly increased the solve rate up to 60%, while late onset and lower grades of hearing loss yielded significantly fewer diagnoses. Regarding genetic diagnoses, autosomal-dominant genes accounted for 37%, autosomal-recessive genes for 60%, and X-linked genes for 3% of the solved cases. Syndromic/nonsyndromic hearing loss mimic genes were affected in 27% of the genetic diagnoses. CONCLUSIONS: The genetic epidemiology of the largest German cohort subjected to comprehensive targeted sequencing for hereditary hearing loss to date revealed broad causal gene and variant spectra in this population. Targeted hearing loss gene panel analysis proved to be an effective tool for ensuring an appropriate diagnostic yield in a routine clinical setting including the identification of novel variants and medically significant reclassifications. Solve rates were highly sensitive to phenotypic characteristics. The unique population-adapted and balanced age distribution of the cohort favoring late hearing loss onset uncovered a markedly large contribution of autosomal-dominant genes to the diagnoses which may be a representative for other age balanced cohorts in other populations.

来源:Ear Hear,查看原文。版权归原作者所有。

引用

  1. Tropitzsch A, Schade-Mann T, Gamerdinger P, et al. Diagnostic Yield of Targeted Hearing Loss Gene Panel Sequencing in a Large German Cohort With a Balanced Age Distribution from a Single Diagnostic Center: An Eight-year Study. Ear Hear. 2022. PMID: 34753855. doi:10.1097/AUD.0000000000001159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。